AnaptysBio: The Royalty Waterfall Is About To Reverse

Impact · against what's priced in

AnaptysBio shifts to a high-margin royalty management model with a clear path to full cash flow retention by mid-2027. The elimination of R&D burn and the accumulation of $140M in net cash fundamentally re-rate the company's profitability profile.

ANAB+0.70: No priced-in read yet
In context: The transition to a 95% targeted EBIT margin and the removal of R&D burn, paired with the upcoming 2027 completion of the Sagard obligation, creates a significant valuation lift.
Read from the article alone

AnaptysBio: The Royalty Waterfall Is About To Reverse

cash flow
biotech
pharmaceuticals
ANAB
ebit margin
royalties
spin off

Search tags

AnaptysBio: The Royalty Waterfall Is About To Reverse

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AnaptysBio: The Royalty Waterfall Is About To Reverse

What matters in this story

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Connected tickers

Track these names every morning.

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights

AnaptysBio: The Royalty Waterfall Is About To Reverse

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

AnaptysBio: The Royalty Waterfall Is About To Reverse

What matters in this story

Next reads from the same story arc

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

How each ticker is affected

Connected tickers

Track these names every morning.

AVXL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Anavex (AVXL) Investors of Securities Class Action Lawsuit Deadline on November 30, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label

Takeda's ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Unicycive Therapeutics, Inc. Class Action Reminder - Robbins LLP Encourages UNCY Investors to Contact the Firm About Their Rights